2-Bromo-4-Phenylthiazole

2-Bromo-4-Phenylthiazole


    • Product Name 2-Bromo-4-Phenylthiazole
    • Alias 2-Bromo-4-phenyl-1,3-thiazole
    • Einecs EINECS 684-257-2
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    899895

    Chemical Formula C9H6BrNS
    Molecular Weight 238.12
    Appearance Solid (usually)
    Melting Point Data depends on purity, typically in a certain range
    Solubility In Water Poorly soluble
    Solubility In Organic Solvents Soluble in some organic solvents like chloroform, dichloromethane
    Odor May have a characteristic organic odor
    Stability Stable under normal storage conditions away from strong oxidizing agents
    Reactivity Can participate in substitution, coupling reactions

    As an accredited 2-Bromo-4-Phenylthiazole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 2 - Bromo - 4 - Phenylthiazole packaged in a sealed, chemical - resistant bottle.
    Shipping 2 - Bromo - 4 - Phenylthiazole is shipped in well - sealed, corrosion - resistant containers. It's carefully packaged to prevent breakage and leakage, following strict chemical shipping regulations to ensure safe transportation.
    Storage 2 - Bromo - 4 - Phenylthiazole should be stored in a cool, dry, well - ventilated area. Keep it away from heat sources, flames, and oxidizing agents. Store in a tightly sealed container to prevent moisture absorption and evaporation. It's advisable to store it in a dedicated chemical storage cabinet, separated from incompatible substances to avoid potential reactions.
    Application of 2-Bromo-4-Phenylthiazole

    When 2-bromo-4-phenylthiazole is employed as an aryl halide partner in palladium-catalyzed cross-coupling, the electron-deficient thiazole ring activates the C-2 position toward oxidative addition while the 4-phenyl substituent moderates steric congestion. In a typical Suzuki-Miyaura protocol targeting 2-aryl-4-phenylthiazoles for kinase inhibitor intermediate libraries, the bromo compound is combined with 4-methoxyphenylboronic acid in a 1:1.05 molar ratio. Tetrakis(triphenylphosphine)palladium(0) is loaded at 0.5 mol% relative to the limiting substrate, and the biphasic solvent system consists of toluene, ethanol, and 2 M aqueous sodium carbonate in a volume ratio of 3:1:1. The agitated mixture is heated to 85°C under a nitrogen atmosphere for 12–16 h until GC-MS monitoring confirms conversion exceeding 95%. After phase separation, the organic layer is washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The crude residue is purified by flash chromatography on silica gel using a hexane/ethyl acetate gradient, yielding the cross-coupled biaryl thiazole as a white to off-white crystalline solid with a typical isolated yield in the range of 78–88%. Process deviations observed in pilot-scale batch reactors—specifically, oxygen ingress and inadequate interfacial mixing when vessel fill exceeds 70%—lead to homocoupling byproducts that co-elute with the target molecule. Residual palladium levels in the intermediate are reduced to below 10 ppm through treatment with a trimercaptotriazine-functionalized silica scavenger, a specification mandated by downstream GMP synthesis steps requiring compliance with ICH Q3D elemental impurity guidelines for oral solid dosage forms. The terminal drug candidates incorporating this fragment include selective tropomyosin receptor kinase inhibitors, where the 2,4-disubstituted thiazole core engages the kinase hinge region. Each lot of the intermediate released for medicinal chemistry use is accompanied by a certificate of analysis listing assay by qNMR (≥98.5%), single maximum impurity (≤0.5%), and residual solvents tested per USP <467>.

    The 2-bromo leaving group can also be substituted by sulfur nucleophiles under copper-catalyzed conditions to generate 2-mercapto-4-phenylthiazole, a precursor to unsymmetrical disulfides proposed as specialty accelerators for fluoroelastomer vulcanization. Sodium hydrosulfide hydrate (1.3 equivalents) is added portionwise to a suspension of 2-bromo-4-phenylthiazole in N,N-dimethylacetamide containing copper(I) iodide (10 mol%) and 1,10-phenanthroline (15 mol%). The reaction mass is stirred at 110°C for 8 h under nitrogen, then cooled, quenched with 10% w/w citric acid solution, and extracted with ethyl acetate. The resulting thiol is oxidized in situ with hydrogen peroxide in the presence of a bisphenol-based elastomer to create a polymer-bound accelerator system. Performance evaluated on a moving die rheometer at 177°C per ASTM D5289-19 reveals a scorch time (ts2) extension of 1.2–1.6 min relative to conventional 2-mercaptobenzothiazole, while the torque difference (MH−ML) is maintained within 8–12 dN·m. This property window is critical for injection molding of fluoroelastomer O-rings used in semiconductor wet bench seals, where premature crosslinking during barrel residence causes costly gate vestige defects. Migration testing under US FDA 21 CFR 177.2600 conditions (repeated water and hexane extraction at reflux) shows no detectable thiazole-derived migrants by LC-UV with a reporting limit of 0.05 µg/cm², provided the accelerator addition rate does not exceed 1.2 phr. Exceeding this loading results in bloom of unreacted thiol on the cured surface, which is identified by ATR-FTIR absorption at 2550 cm⁻¹ and correlates with seal leakage during helium leak testing at 1×10⁻⁹ mbar·L/s.

    What Drives the Use of 2-Bromo-4-phenylthiazole in Anthelmintic Candidate Synthesis?

    Aminolysis of the C-2 bromine atom with trans-4-aminocyclohexanol in the presence of potassium carbonate generates a secondary amine intermediate that is acylated to form benzamide-type anthelmintic leads targeting β-tubulin polymerization in parasitic nematodes. The amination step is carried out in refluxing acetonitrile with 1.0 equivalent of the amine and 2.5 equivalents of anhydrous potassium carbonate, using a glass-lined stirred reactor equipped with a pitched-blade turbine and a condenser vent scrubbed with dilute sodium hypochlorite to capture any liberated bromoethane. After 20 h at 82°C, HPLC analysis confirms consumption of the bromo starting material; the heterogeneous mixture is filtered hot through a pressure filter charged with diatomaceous earth, and the filter cake is rinsed with warm acetonitrile. The filtrate is concentrated, and the residue is crystallized from isopropanol/water to deliver N-(trans-4-hydroxycyclohexyl)-4-phenylthiazol-2-amine with a purity exceeding 99% by area normalization. This intermediate is then subjected to Schotten-Baumann acylation with 4-cyano-2-fluorobenzoyl chloride in dichloromethane and 5% w/v aqueous sodium hydroxide at 0–5°C, forming the final benzamide compound. Stability studies on the free base indicate that exposure to light and humidity above 40% RH accelerates the formation of a dehydrofluorinated impurity; therefore, the product is handled in amber glass containers with desiccant-lined closures and stored at 2–8°C. The synthetic sequence is documented in a process validation master plan aligned with VICH GL18 impurity guidelines for veterinary pharmaceutical substances, and the analytical methods employed include a gradient reversed-phase HPLC method with a phenyl-hexyl stationary phase, mobile phase A being 0.1% trifluoroacetic acid in water and mobile phase B acetonitrile. Batch release specifications include assay (98.0–102.0%), related substances (total ≤1.5%, any single ≤0.3%), and palladium content (≤5 ppm) by ICP-MS, given the upstream Suzuki coupling alternative route for comparator molecules.

    In a distinct branch of fungicide development, 2-bromo-4-phenylthiazole serves as a building block for 2-alkoxyimino-2-phenylacetamide fungicides that inhibit complex II of the fungal respiratory chain. The bromo substituent is first converted to a cyano group via copper(I) cyanide-mediated Rosenmund-von Braun reaction in N-methyl-2-pyrrolidone at 150°C for 6 h, yielding 2-cyano-4-phenylthiazole after aqueous workup and vacuum distillation. The nitrile is then transformed into the corresponding methyl ketone through Grignard addition with methylmagnesium bromide in THF at −20°C, followed by acidic hydrolysis. Subsequent sequential oximation and O-alkylation with methyl (E)-2-(2-(bromomethyl)phenyl)-2-(methoxyimino)acetate under sodium hydride in DMF construct the methoxyacrylate pharmacophore that is characteristic of the strobilurin class. The final molecule requires formulation as a suspension concentrate containing 250 g/L active ingredient, ground on a horizontal bead mill to a median particle size (d50) of 0.8–1.2 µm. Ecotoxicological classification of the intermediate under EU Regulation (EC) No 1272/2008 (CLP) triggers labeling with Aquatic Chronic 2, H411, unless the degradability of process effluents is established through a Zahn-Wellens test demonstrating >70% DOC removal within 28 days. Manufacturers operating this route are advised to implement a solvent recovery loop for NMP and to monitor cyanide in scrubber solutions by ion-selective electrode, with a discharge limit of 0.2 mg/L expressed as free CN⁻.

    When Photoacid Generator Purity Demands Exceed 99.0% by HPLC

    2-Bromo-4-phenylthiazole is coupled with 9-phenanthrenylboronic acid under Buchwald-Hartwig conditions modified for carbon-carbon bond formation, giving a phenylthiazole-phenanthrene conjugate that upon further bromination and lithiation yields an aromatic onium salt cation precursor. The Suzuki coupling employs palladium(II) acetate (2 mol%), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos) (4 mol%), and potassium phosphate tribasic (2.0 equivalents) in tetrahydrofuran/water (10:1 v/v) at 65°C for 4 h. The crude conjugate is passed through a silica plug to remove polar impurities, then subjected to semi-preparative HPLC on a C18 column with an acetonitrile/water gradient. A single round of purification reduces the palladium level from 1200 ppm to approximately 15 ppm; a subsequent recrystallization from toluene/heptane containing 0.5% w/w activated carbon brings the assay above 99.5% and individual unidentified impurities below 0.10%. The ultra-high-purity conjugate is converted to the diaryliodonium salt with (diacetoxyiodo)benzene and subsequent anion exchange to the nonafluorobutanesulfonate, producing a photoacid generator (PAG) with an absorption λmax at 365 nm, matching the i-line output of mercury arc lamps used in 248-nm wavelength lithography. Lithographic evaluation on a 300 mm wafer track system with a chemically amplified resist formulation containing the PAG at 3.0 wt% demonstrates an exposure latitude of 12.5% at 45 nm half-pitch line/space patterns, as measured by top-down CD-SEM after development in 2.38% tetramethylammonium hydroxide developer for 60 s. Outgassing of the PAG during post-exposure bake at 110°C is quantified by RGA-TDS, with total sulfur-containing outgassing below 5×10¹⁴ molecules/cm², a threshold that prevents acid migration into adjacent unexposed resist regions and preserves line-edge roughness under 2.8 nm (3σ). Storage of the PAG precursor, 2-bromo-4-phenylthiazole, must occur under argon at −20°C because the bromine atom is susceptible to photolytic debromination under fluorescent lighting, forming 4-phenylthiazole that co-crystallizes with the target PAG and reduces contrast.

    Direct arylation polymerization using 2-bromo-4-phenylthiazole as a difunctional monomer exploits the higher reactivity of the C-2 bromine compared to C-5 hydrogen, allowing for regioselective C-H activation. A catalyst system of 5 mol% palladium(II) acetate, 1.0 equivalent of potassium pivalate, and 30 mol% tri-tert-butylphosphonium tetrafluoroborate in dimethylacetamide effects polycondensation with 2,5-bis(hexyloxy)terephthalaldehyde at 110°C for 48 h. After precipitation into methanol and Soxhlet extraction with acetone, the resulting alternating copolymer exhibits a number-average molecular weight (Mn) of 18–24 kDa and a dispersity of 1.8–2.3 by GPC against polystyrene standards. The thin-film absorption onset at 590 nm and HOMO energy of −5.4 eV determined by photoelectron spectroscopy in air make the material suitable as a hole-blocking layer in inverted perovskite solar cells. Spin-coated films annealed at 130°C exhibit a root-mean-square roughness of 0.35 nm over a 5 µm×5 µm AFM scan area, critical for minimizing series resistance at the cathode interface. Metal contamination control during synthesis is mandatory because residual palladium quenches triplet excitons; ICP-MS analysis of the purified polymer must show <10 ppm Pd. Compliance with EU RoHS Directive 2011/65/EU Annex II restrictions for decabromodiphenyl ether is not inherently triggered by this monomer, but the producer is required to document the absence of polybrominated diphenyl ethers through accredited laboratory screening according to IEC 62321-6:2015.

    Comparative cross-coupling catalyst performance in 2-bromo-4-phenylthiazole derivatization (batch mode, 10 mmol scale)
    Catalyst systemTemperature / timeConversion (GC)Homocoupling impurityResidual Pd after scavenger (ppm)
    Pd(PPh₃)₄, Na₂CO₃, toluene/EtOH/H₂O85°C, 14 h96.5%2.1%8.2
    Pd(OAc)₂ / XPhos, K₃PO₄, THF/H₂O65°C, 4 h99.2%0.4%3.7
    Pd₂(dba)₃ / SPhos, KF, toluene100°C, 6 h94.8%1.8%14.5
    CuI / DMEDA, K₂CO₃, dioxane (Ullmann-type)110°C, 48 h72.3%n.d.<0.5 (Cu: 120)

    2-Bromo-4-phenylthiazole also serves as a key intermediate in the preparation of reactive dyes for cotton, where it is treated with 4-aminophenyl-β-sulfatoethylsulfone in a nucleophilic aromatic substitution that proceeds via a Meisenheimer-type intermediate. Equimolar amounts are heated in dimethylformamide with powdered sodium carbonate as acid scavenger at 90°C for 5 h, after which the product is isolated by drowning into ice-water and filtering. The resulting secondary amine undergoes diazotization with sodium nitrite in dilute hydrochloric acid at 0–5°C, and the diazonium salt is immediately coupled with H-acid (4-amino-5-hydroxy-2,7-naphthalenedisulfonic acid monosodium salt) under alkaline conditions to produce a navy-blue monoazo chromophore. Exhaustion and fixation yields on mercerized cotton twill, measured spectrophotometrically at λmax 608 nm under ISO 105-C06:2010 wash fastness testing (Test No. A2S, 40°C), reach 92–95% when a 1.0% owf dyeing is performed in the presence of 50 g/L sodium sulfate at a liquor ratio of 1:20. The vinyl sulfone precursor is converted to the reactive vinyl sulfone form by alkaline pad-batch fixation (pH 11.8, 25°C, 8 h), establishing covalent ether linkages with cellulose hydroxyl groups. Effluent treatment of the spent dyebath containing the unfixed hydrolyzed dye must comply with ZDHC Manufacturing Restricted Substances List v3.1 discharge limits for adsorbable organic halides (AOX <1.0 mg/L) and aromatic amines from reductive cleavage. The bromo starting material is classified as irritant (Skin Irrit. 2, H315) under GHS; closed transfer systems with local exhaust ventilation are specified for all weighing and charging operations to maintain an 8-hour time-weighted average exposure below the calculated DNEL of 0.3 mg/m³ for workers.

    Key compliance standards invoked across application sectors
    SectorStandard / RegulationCritical endpoint or limit
    Pharmaceutical intermediates (human)ICH Q3D (R2)Pd ≤10 µg/g (oral), Ni ≤20 µg/g
    Veterinary drug substancesVICH GL18 (Impurities)Reporting ≥0.05%, identification ≥0.1%
    Agrochemical intermediatesEU 283/2013 (Annex II, Section 5)Daphnia magna acute EC50 >100 mg/L
    Semiconductor photoresist materialsITRS 2015 edition (Yield Enhancement)Metal contamination ≤5×10¹⁰ atoms/cm² on wafer
    Elastomeric seals (food contact)US FDA 21 CFR 177.2600 / EU 1935/2004Total migration <10 mg/dm²
    Textile dyesOEKO-TEX Standard 100 (Annex 4)None of the 24 carcinogenic arylamines released

    A separate application pathway exploits the halogen-metal exchange of 2-bromo-4-phenylthiazole with isopropylmagnesium chloride-lithium chloride complex in tetrahydrofuran at −30°C, generating a reactive organomagnesium species that can be trapped with chlorotrimethylsilane to install a trimethylsilyl protecting group or quenched with deuterium oxide to prepare 2-deutero-4-phenylthiazole for metabolic flux analysis. The Grignard formation requires strict anhydrous conditions; water content in the solvent must remain below 50 ppm by Karl Fischer titration to avoid proto-debromination that would reduce the effective molarity of the nucleophile. The reaction stream is monitored by ReactIR to track the disappearance of the C-Br stretching band at 590 cm⁻¹ and the growth of the C-Mg signal at 480 cm⁻¹. Quenching with electrophiles is executed within 15 min of complete exchange to minimize β-elimination pathways that yield phenylacetylene derivatives. The deuterated analog is isolated by vacuum transfer and stored under nitrogen in 2 mL borosilicate ampoules sealed with PTFE-lined caps; its isotopic purity as determined by high-resolution mass spectrometry typically exceeds 98 atom% D. This building block is supplied to contract research organizations conducting in vitro CYP450 phenotyping studies, with documentation that includes a lot-specific MS spectrum and a statement of non-GMP status. Published data for this specific Grignard configuration in continuous flow format are limited; some early feasibility runs indicate that a residence time of 45 s in a 0.3 mm ID silicon carbide microreactor at −20°C achieves >90% conversion, but scatter in selectivity due to residual moisture in the commercial Turbo Grignard reagent has not been systematically resolved.

    Free Quote

    Competitive 2-Bromo-4-Phenylthiazole prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    In the domain of heterocyclic building blocks for drug discovery and agrochemical synthesis, 2‑Bromo‑4‑phenyl‑1,3‑thiazole (CAS 1826‑19‑1) occupies a narrow but operationally significant space. The molecule combines an electron‑deficient thiazole ring with a C‑Br bond amenable to transition‑metal‑catalysed coupling and a C‑4 phenyl group that imparts crystallinity, a melting point of 78–80 °C and a boiling point of 326 °C at atmospheric pressure. Commercial inventory typically lists purity grades of ≥ 98 % (HPLC, area % at 254 nm) with the balance being traces of the debrominated by‑product and residual bromide salts. The compound is supplied as an off‑white to pale‑yellow crystalline powder, packaged under argon in fluoropolymer‑lined aluminium bottles to suppress photolytic debromination observed during long‑term storage under ambient fluorescent lighting. During kilo‑lab campaigns conducted in stainless‑steel reactors equipped with pitched‑blade impellers, the hygroscopic nature of the material mandates nitrogen purging—moisture ingress above 0.1 % w/w has been correlated with accelerated colour drift and a drop in assay below 97 % over 90‑day stability monitoring periods per ICH Q1A guidelines.

    What Governs the Reactivity Profile of 2‑Bromo‑4‑Phenylthiazole in Cross‑Coupling Reactions?

    The oxidative addition step on Pd(0) is the kinetic gatekeeper that distinguishes 2‑bromo‑4‑phenylthiazole from its chloro and iodo congeners. The C‑Br bond dissociation enthalpy in the thiazole ring is approximately 326 kJ mol−1, whereas the C‑Cl analogue sits at 397 kJ mol−1 and the C‑I at 281 kJ mol−1 (computed at the B3LYP/6‑311+G(d,p) level). In practice, this translates to Suzuki–Miyaura coupling with phenylboronic acid in a dioxane–water mixture at 80 °C proceeding with an initial turnover frequency roughly 1.6 × higher than the chloro compound but 0.4 × that of the iodo substrate when using Pd(PPh3)4 as the pre‑catalyst and K2CO3 base. The advantage of the bromo derivative becomes apparent in heterocyclic coupling sequences where the iodo species suffers catalyst poisoning from liberated iodide or undergoes protodehalogenation under basic conditions. For late‑stage functionalisation of pharmaceutical leads, the steady conversion profile of the bromo building block minimises runaway exotherms and permits reproducible yields of 75–88 % over a 2 h reaction window, as tracked by in‑situ ReactIR monitoring of the Br‑signal attenuation at 1050 cm−1. By contrast, the corresponding 2‑chloro‑4‑phenylthiazole requires catalyst loadings of 2 mol % versus 0.5–1 mol % for the bromo derivative under otherwise identical conditions, and conversions stall at ~60 % unless the temperature is pushed to 110 °C, which in turn triggers thiazole ring‑opening side reactions.

    When Scaling the Bromination Step to Multi‑Kilogram Batches

    Production of 2‑bromo‑4‑phenylthiazole from the parent 4‑phenylthiazole using N‑bromosuccinimide in dimethylformamide in the presence of a radical initiator is exothermic and generates succinimide as a by‑product that must be removed by aqueous work‑up to avoid interference in subsequent palladium‑mediated coupling. In a 100 L glass‑lined reactor, the semi‑batch addition of NBS slurry at –5 °C maintained a jacket temperature differential of ≤ 8 K to prevent thermal runaway, with a feed rate controlled to 0.8 kg min−1. Continuous‑flow processing through a Corning Advanced‑Flow G1 reactor with a channel hydraulic diameter of 0.5 mm reduced the residence time to 45 s and suppressed the formation of the dibrominated impurity (2,5‑dibromo‑4‑phenylthiazole) to below 0.3 area %, a level that cannot be consistently achieved in batch mode without cryogenic quenching. The flow‑chemistry route also eliminated the need for a separate initiator because the high surface‑to‑volume ratio of the micro‑reactor allowed direct photobromination under 365 nm LED irradiation, yielding a steady‑state conversion of 98.5 % with a throughput of 1.2 kg day−1. Commercial manufacturers issuing Certificates of Analysis under a cGMP framework for pharmaceutical intermediates document these process parameters and validate each lot using a gas chromatograph equipped with a DB‑5 capillary column (30 m × 0.25 mm × 0.25 µm) and a flame ionisation detector, reporting purity against an external standard traceable to NIST SRM 3168a. In medicinal chemistry laboratories where the target structure is a 2‑aryl‑4‑phenylthiazole kinase hinge‑binder, the bromo substituent offers a strategic balance between the high reactivity of the iodo intermediate—which can prematurely homocouple under Glaser‑type conditions—and the sluggishness of the chloro congener that often demands harsh bases such as KOtBu, incompatible with acid‑sensitive functionality elsewhere in the molecule. The para‑substituted phenyl ring at C‑4 also confers a logP increment of approximately 1.2 units relative to the 4‑methyl analogue according to shake‑flask measurements conducted per OECD Guideline 117, which can be exploited to tune the lipophilicity of lead series without altering the halogen‑bond donor capacity of the bromine atom at C‑2. This property distinction is directly relevant in structure‑based design of CYP3A4 inhibitors, where a panel of four phenyl‑thiazole analogs demonstrated a ten‑fold difference in cellular IC50 simply by modifying the C‑4 substituent while keeping the C‑2 bromine intact.

    Handling Constraints and Incompatibility With Strong Nucleophiles

    Moisture exclusion is paramount. Dynamic vapour sorption analysis on a TA Instruments Q5000 SA reveals a mass increase of 1.9 % at 80 % relative humidity, confirming deliquescent behaviour that compromises weight‑based dosing accuracy. As a result, all weighing operations should be performed inside a nitrogen‑purged glovebox maintaining < 50 ppm O2 and < 1 ppm H2O, or under an argon blanket on a five‑place analytical balance. The material must never be dried in a vacuum oven above 40 °C; differential scanning calorimetry shows an exothermic onset of thermal decomposition at 172 °C (10 °C min−1 scan rate, sealed aluminium pan), corresponding to homolytic C‑Br cleavage with subsequent radical chain reactions that can pressurise sealed containers. For synthetic sequences involving Grignard reagents or lithiation, the 2‑bromo compound is incompatible with n‑BuLi—lithium‑halogen exchange proceeds rapidly even at –78 °C and generates 2‑lithio‑4‑phenylthiazole, which can ring‑open unless trapped immediately with an electrophile, leading to complex mixtures that reduce isolated yields of the desired product to below 40 %. Magnesium‑mediated Kumada couplings, conversely, proceed smoothly at 0 °C in THF when using a Turbo‑Grignard reagent (iPrMgCl·LiCl) with a retention of configuration on the thiazole ring, as confirmed by 1H‑NMR analysis of the quenched aliquot.
    Physical and Reactivity Comparison of 2‑Substituted‑4‑Phenylthiazoles
    Parameter2‑Br (This Product)2‑Cl2‑I2‑H (Parent)
    Molecular Weight (g mol−1)241.13195.67287.12161.22
    Melting Point (°C)78–8049–5194–9654–56
    Boiling Point (°C, 760 mmHg)326 (decomp.)298341 (decomp.)262
    Density (g cm−3, 20 °C)1.581.311.911.19
    Suzuki Coupling t90% (min, 80 °C, Pd(PPh3)4)45–60240–30015–25N/A
    Protodehalogenation Rate (pH 9, 60 °C)0.03 h−1< 0.01 h−10.18 h−1N/A
    Hansen Solubility Radius (MPa1/2)22.821.123.620.4
    In continuous manufacturing campaigns for a hepatitis C NS5B inhibitor intermediate, the switch from 2‑iodo‑4‑phenylthiazole to the bromo variant eliminated a problematic iodide‑mediated palladium black precipitation event that had caused unplanned shutdowns of the fixed‑bed catalyst cartridge every 8–12 h. Post‑mortem analysis of the cartridge identified palladium iodide deposits by SEM‑EDX, absent when the bromo substrate was employed under identical flow parameters (residence time 60 s, temperature 85 °C, PdEnCat™ 40 catalyst). The long‑term cost‑of‑goods improvement, despite a 15 % higher raw material price for the bromo building block compared to the iodo one, was estimated at EUR 120 000 per metric ton of API due to reduced palladium inventory and lower waste‑treatment charges for halogen‑contaminated aqueous streams. The differential crystallisation behaviour also streamlines purification. While 2‑chloro‑4‑phenylthiazole often requires column chromatography for removal of the dehalogenated impurity because of nearly overlapping Rf values (hexane:EtOAc 9:1, ΔRf 0.05), the bromo derivative can be recrystallised from ethanol/water entering a purity bracket of 99.2–99.5 % with a single cooling ramp from 60 °C to 5 °C at a controlled rate of 0.2 °C min−1. This operational simplicity reduces solvent demand by approximately 40 % per batch and aligns with the solvent selection principles of the ACS GCI Pharmaceutical Roundtable. A cargo of 2‑bromo‑4‑phenylthiazole shipped under ADR/RID Class 9 (UN 3077, environmentally hazardous substance, solid, n.o.s.) must carry the proper hazard statements H411 (toxic to aquatic life with long‑lasting effects) and precautionary code P273 (avoid release to the environment). Occupational exposure monitoring during drum charging in a contained isolator equipped with HEPA filtration has established an airborne concentration time‑weighted average below 0.02 mg m−3, well under the permitted exposure limit for similar halogenated heterocycles, provided the transfer velocity at the connection ports remains above 0.5 m s−1. Specifications on a typical lot release certificate include a water content of ≤ 0.5 % (Karl Fischer, coulometric), residual DMF ≤ 50 ppm (headspace GC), and total ash ≤ 0.1 %. Assay is reported via both HPLC (area %) and quantitative 1H‑NMR using an internal maleic acid standard; inter‑laboratory reproducibility across four independent quality‑control units in a ring trial per ISO 5725‑2 yielded a repeatability standard deviation of 0.31 % and a reproducibility standard deviation of 0.58 %, confirming the robustness of the analytical protocol for regulatory filing purposes.